{"created":"2023-05-18T10:11:28.456404+00:00","id":3216,"links":{},"metadata":{"_buckets":{"deposit":"ae78c55d-4fba-446c-9d31-b025de541667"},"_deposit":{"created_by":1,"id":"3216","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"3216"},"status":"published"},"_oai":{"id":"oai:yamanashi.repo.nii.ac.jp:00003216","sets":["205:251:306"]},"author_link":["15135","15137","15134","15136"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1989","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"59","bibliographicPageStart":"55","bibliographicVolumeNumber":"4","bibliographic_titles":[{"bibliographic_title":"山梨医科大学雑誌"},{"bibliographic_title":"山梨医科大学雑誌","bibliographic_titleLang":"en"}]}]},"item_10001_creator_2":{"attribute_name":"著者名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Tawata, Masato"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Aida, Kaoru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shindo, Hideo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Onaya, Toshimasa"}],"nameIdentifiers":[{}]}]},"item_10001_description_5":{"attribute_name":"内容","attribute_value_mlt":[{"subitem_description":"Hyperaggregability of platelets observed in diabetic patients has been speculated as one of the causes of chronic diabetic complications. Gliclazide, an oral hypoglycemic agent, inhibited the platelet aggregation, ATP release, the phosphorylation of 40 K dalton protein and a thrombin-induced increase of intraplatelet calcium in vitro. Although a high concentration of gliclazide (500 μg/ml) was required to inhibit the increase of intraplatelet calcium induced by O.1 U/ml thrombin, the inhibitory effect of gliclazide on platelet aggregation induced by 0.5 μg/ml collagen, was observed at a concentration as low as 1 μg/ml. The results of our experiments demonstrated that gliclazide directly inhibits the platelet aggregation at a concentration attainable by the usual oral dose of gliclazide. Therefore, it is likely that gliclazide has a favorable action on diabetic complications, not only by reducing blood glucose level, but also by reducing platelet hyperaggregability.","subitem_description_type":"Other"}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.34429/00003209","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"山梨医科大学医学会"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN10044054","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0912-0025","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-27"}],"displaytype":"detail","filename":"AN10044054_04_02_02.pdf","filesize":[{"value":"905.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"AN10044054_04_02_02.pdf","url":"https://yamanashi.repo.nii.ac.jp/record/3216/files/AN10044054_04_02_02.pdf"},"version_id":"539f399e-cde3-461c-98c8-29c3d063dbe4"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Gliclazide"},{"subitem_subject":"oral hypoglycemic agent"},{"subitem_subject":"Anti-platelet action"},{"subitem_subject":"Diabetic complications"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"<Original Article> Anti-Platelet Action of Gliclazide, an Oral Hypoglycemic Agent, and its Possible Mechanism","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"<Original Article> Anti-Platelet Action of Gliclazide, an Oral Hypoglycemic Agent, and its Possible Mechanism"}]},"item_type_id":"10001","owner":"1","path":["306"],"pubdate":{"attribute_name":"公開日","attribute_value":"2010-05-18"},"publish_date":"2010-05-18","publish_status":"0","recid":"3216","relation_version_is_last":true,"title":["<Original Article> Anti-Platelet Action of Gliclazide, an Oral Hypoglycemic Agent, and its Possible Mechanism"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-10-11T07:42:27.623331+00:00"}